Thryvv : ratio page
Bafna Pharma
Financial Ratios
View
Order
Financial Ratios | Mar2020 | Mar2019 | Mar2018 | Mar2017 | Mar2016 |
|---|---|---|---|---|---|
Valuation Parameters: | |||||
PE(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PCE(x) | 1.52 | -1.63 | -5.12 | -3.62 | -5.42 |
Price/Book(x) | -0.49 | 1.36 | 1.75 | 1.43 | 0.98 |
Yield(%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Net Sales(x) | -0.08 | 1.59 | 2.33 | 2.08 | 1.57 |
EV/Core EBITDA(x) | -2.28 | -5.47 | -28.90 | -28.88 | 53.52 |
EV/EBIT(x) | 1.88 | -4.29 | -14.13 | -15.17 | -56.51 |
EV/CE(x) | -0.05 | 0.58 | 0.79 | 0.76 | 0.69 |
MCap / Sales | 0.05 | 0.59 | 1.40 | 0.85 | 0.65 |
Growth Ratio: | |||||
Net Sales Growth(%) | -2.65 | -7.51 | -27.39 | -23.86 | -38.53 |
Core EBITDA Growth(%) | 111.65 | -233.99 | 18.63 | -287.13 | -91.20 |
EBIT Growth(%) | 88.94 | -107.96 | 12.55 | -276.12 | -112.10 |
PAT Growth(%) | 90.27 | -14.49 | 13.11 | -28.52 | -343.44 |
EPS Growth(%) | -9.16 | -18.78 | 30.85 | -36.07 | -327.07 |
Financial Stability Ratios: | |||||
Total Debt/Equity(x) | -0.71 | 2.43 | 1.23 | 2.13 | 1.41 |
Current Ratio(x) | 2.11 | 0.68 | 0.81 | 0.95 | 1.29 |
Quick Ratio(x) | 1.44 | 0.55 | 0.64 | 0.74 | 1.11 |
Interest Cover(x) | -18.72 | -7.60 | -1.12 | -0.77 | -0.18 |
Total Debt/Mcap(x) | 1.44 | 1.78 | 0.70 | 1.49 | 1.44 |
Operational & Financial Ratios: | |||||
Earnings Per Share (Rs) | -9.17 | -8.40 | -7.07 | -10.23 | -7.52 |
CEPS(Rs) | 5.85 | -6.71 | -5.47 | -8.17 | -5.51 |
DPS(Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book NAV/Share(Rs) | -17.93 | 8.06 | 16.03 | 20.73 | 30.57 |
Tax Rate(%) | 0.00 | -5.84 | -14.90 | 4.43 | 1.16 |
Margin Ratios: | |||||
Core EBITDA Margin(%) | 2.88 | -29.97 | -74.48 | -8.76 | 0.60 |
EBIT Margin(%) | -4.21 | -37.06 | -16.48 | -13.40 | -2.74 |
Pre Tax Margin(%) | -4.43 | -41.93 | -31.20 | -30.71 | -17.73 |
PAT Margin (%) | -4.43 | -44.38 | -35.85 | -29.34 | -17.53 |
Cash Profit Margin (%) | 3.26 | -36.41 | -27.42 | -22.98 | -11.90 |
Performance Ratios: | |||||
ROA(%) | -1.97 | -15.02 | -10.68 | -10.50 | -7.72 |
ROE(%) | -25.42 | -67.95 | -44.15 | -40.67 | -23.51 |
ROCE(%) | -2.99 | -21.59 | -7.42 | -6.77 | -1.70 |
Asset Turnover(x) | 0.45 | 0.34 | 0.30 | 0.36 | 0.44 |
Sales/Fixed Asset(x) | 0.58 | 0.57 | 0.59 | 0.83 | 1.10 |
Working Capital/Sales(x) | 2.24 | -1.95 | -4.25 | -15.47 | 3.17 |
Efficiency Ratios: | |||||
Fixed Capital/Sales(x) | 1.73 | 1.75 | 1.69 | 1.20 | 0.91 |
Receivable days | 132.64 | 205.45 | 301.99 | 335.02 | 330.94 |
Inventory Days | 88.92 | 83.48 | 106.06 | 91.14 | 68.66 |
Payable days | 587.94 | 519.65 | 287.43 | 227.06 | 231.59 |